Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2687595 | 1.00 | GAA (0.38) | GAAALDH1A1TP53MAPTHPGD | |
| Hydrochloric Acid SCHEMBL28335790 | 0.98 | GAA (0.37) | GAAALDH1A1TP53MAPTHPGD | |
| SCHEMBL14277696 | 0.83 | ALDH1A1 (0.33) | GAAALDH1A1TP53MAPTHPGD | |
| SCHEMBL9888827 | 0.80 | GAA (0.39) | GAAALDH1A1CYP19A1GPBAR1LMNA | |
| SCHEMBL14001473 | 0.80 | GAA (0.39) | GAAALDH1A1CYP19A1GPBAR1LMNA | |
| SCHEMBL14275616 | 0.79 | CYP19A1 (0.53) | GAAALDH1A1TP53MAPTHPGD | |
| SCHEMBL15474210 | 0.79 | SMN1; SMN2 (0.53) | GAAALDH1A1TP53HPGDHTT | |
| SCHEMBL23641773 | 0.79 | GAA (0.40) | GAAALDH1A1MAPTGPBAR1LMNA | |
| SCHEMBL15474211 | 0.79 | GAA (0.38) | GAAALDH1A1CYP19A1GPBAR1LMNA | |
| SCHEMBL15474216 | 0.78 | SMN1; SMN2 (0.46) | GAAALDH1A1TP53MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | COMPASS HORIZON FUNDING COMPANY LLC | 2010-06-10 | — | — | US | claimed |
| EP-2079727-B1 | KINASE INHIBITOR COMPOUNDS | XCOVERY INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144768-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K9, MAP3K1, MAP3K8 | GAA 1840/4885ALDH1A1 3675/4885TP53 747/4885 |
| US-20140044672-A1 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER | CSF3R, GMFG, CSF1R | GAA 290/4885ALDH1A1 2146/4885TP53 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.